Preventive effect of gomisin J from Schisandra chinensis on angiotensin II-induced hypertension via an increased nitric oxide bioavailability

被引:0
作者
Byeong Hyeok Ye
Seung Jin Lee
Young Whan Choi
So Youn Park
Chi Dae Kim
机构
[1] School of Medicine and MRC for Ischemic Tissue Regeneration,Department of Pharmacology
[2] Pusan National University,undefined
[3] College of Natural Resources & Life Sciences,undefined
[4] Pusan National University,undefined
来源
Hypertension Research | 2015年 / 38卷
关键词
angiotensin II; blood pressure; gomisin J; nitric oxide; ROS;
D O I
暂无
中图分类号
学科分类号
摘要
Gomisin J (GJ) is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity. In this study, the authors investigated the effect of GJ on blood pressure (BP) in angiotensin II (Ang II)-induced hypertensive mice. In addition, we determined the relative potencies of gomisin A (GA) and GJ with respect to vasodilatory activity and antihypertensive effects. C57/BL6 mice infused s.c. with Ang II (2 μg kg−1 min−1 for 2 weeks) showed an increase in BP and a decrease in plasma nitric oxide (NO) metabolites. In the thoracic aortas of Ang II-induced hypertensive mice, a decrease in vascular NO was accompanied by an increase in reactive oxygen species (ROS) production. Furthermore, these alterations in BP, plasma concentrations of NO metabolites and in the vascular productions of NO and ROS in Ang II-treated mice were reversed by the co-administration of GJ (1 and 3 μg kg−1 min−1). In in vitro studies, Ang II decreased the cellular concentration of NO, which was accompanied by a reduction in phosphorylated endothelial nitric oxide synthase (eNOS) and an increase in ROS production. These eNOS phosphorylation and ROS production changes in Ang II-treated cells were also reversed by GJ pretreatment (0–3 μg ml−1). Interestingly, the vasodilatory and antihypertensive effects of GJ were more prominent than those of GA. Collectively, an increase in BP in mice treated with Ang II was markedly attenuated by GJ, which was attributed to the preservations of vascular NO bioavailability and eNOS function, and to the inhibition of ROS production in Ang II-induced hypertensive mice.
引用
收藏
页码:169 / 177
页数:8
相关论文
共 243 条
[1]  
John WO(2012)Sympathetic signatures of cardiovascular disease: a blueprint for development of targeted sympathetic ablation therapies Hypertension 59 545-547
[2]  
Marcos T(2012)The influence of oxonate-induced hyperuricemia and allopurinol on behavioral reactions of random-bred mice J Basic Clin Physiol Pharmacol 23 147-151
[3]  
Olga T(2004)Role of endothelial dysfunction in atherosclerosis Circulation 109 III27-III32
[4]  
Sergey S(2009)Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 b1665-824
[5]  
Davignon J(2001)Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299 818-1762
[6]  
Ganz P(2002)Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin Int Immunopharmacol 2 1755-1126
[7]  
Law MR(2008)Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension Antioxid Redox Signal 10 1115-169
[8]  
Morris JK(2005)Angiotensin II and the endothelium: diverse signals and effects Hypertension 45 163-78
[9]  
Wald NJ(2006)Angiotensin II regulates vascular and endothelial dysfunction: recent topics of angiotensin II type-1 receptor signaling in the vasculature Curr Vasc Pharmacol 4 67-2814
[10]  
Fulton D(2011)Oxidative stress and vascular damage in hypertension: role of angiotensin II Int J Hypertens 2011 916310-158